β-Blockers in patients with intermittent claudication and arterial hypertension: Results from the nebivolol or metoprolol in arterial occlusive disease trial

Hypertension

Volumn 58, Issue 2, 2011, Pages 148-154

  Espinola Klein, Christine ^a   Weisser, Gerhard ^a   Jagodzinski, Annika ^a   Savvidis, Savvas ^a   Warnholtz, Ascan ^a   Ostad, Mir Abolfazl ^a   Gori, Tommaso ^a   Munzel, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

receptor blockers; ankle brachial index; arterial hypertension; endothelial dysfunction; intermittent claudication; Peripheral arterial disease; walking distance

Indexed keywords

METOPROLOL; NEBIVOLOL;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BLURRED VISION; BRACHIAL ARTERY; BRADYCARDIA; CLAUDICATION; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; DYSPNEA; EDEMA; ERECTILE DYSFUNCTION; FEMALE; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; VERTIGO; WELLBEING;

ADRENERGIC BETA-ANTAGONISTS; ANKLE BRACHIAL INDEX; ANTIHYPERTENSIVE AGENTS; ARTERIAL OCCLUSIVE DISEASES; BENZOPYRANS; BLOOD PRESSURE; BRACHIAL ARTERY; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; INTERMITTENT CLAUDICATION; MALE; METOPROLOL; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 80051470976     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.169169     Document Type: Article

References (39)

1. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, Pittrow D, von Stritzky B, Tepohl G, Trampisch HJ. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004;172:95-105. (Pubitemid 38058606)
2. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110: 738-743. (Pubitemid 39056275)
3. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 1998;18:185-192. (Pubitemid 28277594)
4. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
5. Espinola-Klein C, Rupprecht HJ, Bickel C, Lackner K, Savvidis S, Messow CM, Munzel T, Blankenberg S. Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction. Circulation. 2008;118: 961-967.
6. Gibbons RJ Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV. ACC/AHA guideline update for the management of patients with chronic stable angina. J Am Coll Cardiol. 2003;41:159-168.
7. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med. 1999;341:1789-1794.
8. Feringa HH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, Galal W, Vidakovic RV, Tangelder MJ, Poldermans D. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol. 2006;47:1182-1187.
9. Aronow WS, Ahn C. Effect of blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol. 2001;87:1284-1286. (Pubitemid 32493871)
10. George CF.-receptor blocking agents. Prescibers J. 1974;14:93-98.
11. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, for the TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007; 45(suppl S):S5-S67. (Pubitemid 46151680)
12. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA Guidelines for the management of patients with peripheral arterial disease. Circulation. 2006;113:e463-654.
13. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Blockade and intermittent claudication: placebo controlled trial of athenolol and nifedipine and their combination. BMJ. 1991;303: 1100-1104.
14. McSorley PD, Warren DJ. Effects of propanolol and metoprolol on the peripheral circulation. BMJ. 1978;2:1598-1600. (Pubitemid 9078322)
15. Lepantalo M. Chronic effects of metoprolol and methyldopa on calf blood flow in intermittent claudication. Br J Clin Pharmacol. 1984;18:90-93. (Pubitemid 14057128)
16. Karnik R, Valentin A, Slany J. Different effects of-1 adrenergic blocking agents with ISA or without ISA on peripheral blood flow. Angiology. 1987;38:296-303. (Pubitemid 17066797)
17. Roberts DH, Tsao Y, McLaughlin GA, Breckenridge A. Placebocontrolled comparison of captopril, atenolol, labentalol, and pindolol in hypertension complicated by intermittent Claudication. Lancet. 1987;2: 650-653. (Pubitemid 17135498)
18. Ubbink DT, Verhaar EE, Lie HK, Legemate DA. Effect of-blockers on peripheral skin microcirculation in hypertension and peripheral vascular disease. J Vasc Surg. 2003;38:535-540. (Pubitemid 41123221)
19. Boström PA, Janzon L, Ohlsson O, Westergren A. The effect of-blockade on leg blood flow in hypertensive patients with intermittent Claudication. Angiology. 1986;37:149-153. (Pubitemid 16097815)
20. Bogaert MG, Clement DL. Lack of influence of propranolol and metoprolol on walking distance in patients with chronic intermittent Claudication. Eur Heart J. 1983;4:203-204. (Pubitemid 13079797)
21. Hiatt WR, Stoll S, Nies AS. Effect of-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. Circulation. 1985;72:1226-1231. (Pubitemid 16126802)
22. Paravastu SCV, Mendonaca DA, da Silva A. Blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38:66-70.
23. Miyajima R, Sano K, Yoshida H.-Adenergic blocking agents and intermittent Claudication: systematic review. Yakugaku Zasshi. 2004;124: 825-831. (Pubitemid 41364362)
24. Radack K, Deck C.-Adrenergic blocker therapy does not worsen intermittent Claudication in subjects with peripheral arterial disease: a metaanalysis of randomized controlled trials. Arch Intern Med. 1991;151: 1705-1707.
25. Breckenridge A, Roberts DH. Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol. J Cardiovasc Pharmacol. 1991;18(suppl 4):S78-S81.
26. Münzel T, Gori T. Nebivolol. The somewhat-different-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54:1491-1499.
27. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation. 2003;108:2093-2098. (Pubitemid 37337585)
28. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized double-blind, crossover study. Circulation. 2001;104:511-514. (Pubitemid 32738117)
29. Münzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med. 2008;40:180-196. (Pubitemid 351482543)
30. Labs K-H, Dormandy JA, Jaeger KA, Stuerzebecher C-S, Hiatt WR. Transatlantic conference in clinical trial guidelines in peripheral arterial disease. Circulation. 1999;100:e75-e81.
31. Marquis P, Comte S, Lehnert P. International validation of the CLAU-S quality of life questionnaire for use in patients with intermittent claudication. Pharmacoeconomics. 2001;19:667-677. (Pubitemid 32531840)
32. Mehta T, Venkata Subramaniam A, Chetter I, McCollum P. Diseasespecific Quality of Life Assessment in Intermittent Claudication. Eur J Vasc Endovasc Surg. 2003;25:202-208. (Pubitemid 36527612)
33. Warnholtz A, Ostad MA, Velich N, Trautmann C, Schinzel R, Walter U, Munzel T. A single dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results from a double-blind, randomized study. Atherosclerosis. 2008;196:689-695.
34. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence of an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
35. Monobe H, Yamanari H, Nakamura K, Ohe T. Effects of low-dose aspirin on endothelial function in hypertensive patients. Clin Cardiol. 2001;24: 705-709. (Pubitemid 33027553)
36. Welten GM, Schouten O, Hoecks SE, Chonchol M, Vidakovic R, van Domburg RT, Bax JJ, van Sambeek MR, Poldermans D. Long-term prognosis of patients with peripheral arterial disease. J Am Coll Cardiol. 2008;51:1588-1596.
37. Narins CR, Zareba W, Moss AJ, Marder VJ, Ridker PM, Krone RJ, Lichstein E. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events about survivors of myocardial infarction. Arch Intern Med. 2004;164:440-446. (Pubitemid 38240709)
38. Singer DRJ, Kite A. Management of hypertension in peripheral arterial disease: does the choice of drugs matter? Eur J Vasc Endovasc Surg. 2008;35:701-708. (Pubitemid 351680158)
39. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholdt JS. Drug therapy for improving walking distance in intermittent Claudication: a systematic review and meta-analysis of robust randomized controlled studies. Eur J Vasc Endovasc Surg. 2009; 38:463-474.